Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Idiopathic Pulmonary Arterial Hypertension Clear all
Completed Not applicable Interventional Results available

Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test

NCT03893500
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Home-based 6 minute walk test
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

NCT01117987
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Nitric Oxide, GeNO Nitrosyl Delivery System

NCT01165047
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

NCT00091598
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 4 Interventional

Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

NCT06409026
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting No phase listed Observational

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

NCT02249923
View directory record Official record
Conditions
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
New York Medical College
Other
Eligibility
1 Day to 21 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 13, 2026, 10:22 PM EDT
Completed No phase listed Observational

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

NCT05339386
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

NCT00963027
View directory record Official record
Conditions
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine, Esomeprazole
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide

NCT01092559
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide generated by the GeNO nitrosyl delivery system
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension

NCT03057028
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

NCT06872112
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
Artesunate
Drug
Lead sponsor
Joseph C. Wu
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

Macitentan in Pulmonary Hypertension of Sickle Cell Disease

NCT02651272
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Disease
Interventions
macitentan
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 13, 2026, 10:22 PM EDT
Not listed No phase listed Observational

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

NCT04489251
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

NCT02279745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 13, 2026, 10:22 PM EDT
Withdrawn Phase 2 Interventional

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

NCT02108743
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension.
Interventions
Albuterol., Normal saline placebo
Drug
Lead sponsor
American Medical Association Foundation
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

NCT03078907
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Anastrozole in Patients With Pulmonary Arterial Hypertension

NCT01545336
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anastrozole, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting Phase 3 Interventional

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

NCT07613099
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury, Pulmonary Arterial Hypertension, Cardiovascular Diseases
Interventions
[18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

NCT04266197
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
Combination Product
Lead sponsor
Respira Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging

NCT01461343
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT imaging, functional PET imaging
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 13, 2026, 10:22 PM EDT
Recruiting No phase listed Observational

Natural History of Noncirrhotic Portal Hypertension

NCT02417740
View directory record Official record
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
26
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 13, 2026, 10:22 PM EDT
Withdrawn Phase 3 Interventional

Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide

NCT02436512
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 13, 2026, 10:22 PM EDT